Globus Medical heads into its August 4 earnings report with short interest at a six-week high and analysts trimming targets across the board — a combination that makes the upcoming print more consequential than usual.
Short sellers have been rebuilding positions steadily since early July. Short interest has climbed 52% over the past month to 6.7% of the free float, with the bulk of that move occurring in the two weeks following the May earnings selloff. The absolute level is not extreme, but the pace of accumulation is notable: shorts added roughly 750,000 shares in the seven days through July 23 alone. The borrow market tells a relaxed story — availability is running near 498%, meaning there are roughly five shares available to lend for every one already borrowed, and cost to borrow is a negligible 0.55%. There is no squeeze pressure here; shorts are adding with ease.
Options traders are not reading from the same page. The put/call ratio has collapsed to 0.25, near the lower end of the 52-week range — a reading that reflects call-heavy positioning rather than the hedged caution you might expect ahead of a name with a recent history of large post-earnings declines. The PCR is essentially flat on its 20-day average of 0.26, so this is not a new development, but it does create an interesting divergence: the short book is building while options positioning stays bullish. One of those camps will be wrong on August 4.
The analyst community has been moving in one direction this month — down. Truist Securities cut its target from $115 to $100 while maintaining Buy, and RBC trimmed from $120 to $115, also keeping Outperform. Stifel holds the most cautious stance, with a Hold rating and an $80 target that sits closest to the current $76.49 price. BMO initiated coverage at Outperform with a $94 target in early July, providing some balance. Across the group, the mean target of $105.75 implies roughly 38% upside from here — a wide gap that reflects genuine disagreement about the recovery timeline. The bear case centres on spine market softness, potential revenue dis-synergies from recent M&A, and slower-than-expected robotics uptake. Bulls point to strong musculoskeletal sales and international expansion. The EV/EBITDA multiple has edged down modestly over the past 30 days to around 8.7x, and the P/E of 15x leaves room for re-rating if execution improves. The analyst recommendation factor scores in the 95th percentile, suggesting the Street remains constructively positioned even after the recent target cuts.
The earnings history sharpens the stakes. The May 7 print delivered a 12.6% one-day loss and a 13.5% five-day loss — the largest single-session decline in the recent record. The February print saw a more modest 1.5% drop on the day, though the stock fell 16% over the following week. That asymmetry — limited upside reaction, heavy downside reaction — is worth sitting with. Closest peer SYK gained 3.2% on the week while GMED slipped 0.7%, continuing a pattern of sector-relative underperformance noted in recent weeks. CNMD also ended the week lower by 1.2%.
The setup heading into August 4 is therefore a tension between a rebuilding short book and still-bullish options positioning, against a backdrop of reduced analyst targets and a stock that has punished longs heavily on its last two earnings releases. The degree to which management can address the spine market narrative — and show any green shoots in robotics — will determine whether the wide gap between price and target begins to close.
See the live data behind this article on ORTEX.
Open GMED on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
